-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice
(2302) Views (574) Full article downloads
Authors: Maddalena Veronesi, Arrigo FG Cicero, Maria Grazia Prandin, Ada Dormi, Eugenio Cosentino, et al
Published Date January 2007
Volume 2007:3(6) Pages 999 - 1005
DOI: http://dx.doi.org/10.2147/VHRM.S
Maddalena Veronesi, Arrigo FG Cicero, Maria Grazia Prandin, Ada Dormi, Eugenio Cosentino, Enrico Strocchi, Claudio Borghi
D. Campanacci Clinical Medicine and Applied Biotechnology Department Alma Mater Studiorum University of Bologna, Italy
Abstract: Persistence on treatment affects the efficacy of antihypertensive treatment. We prospectively investigated the persistence on therapy and the extent of blood pressure (BP) control in 347 hypertensive patients (age 59.4 ± 6 years) randomly allocated to a first-line treatment with: angiotensin-converting enzyme (ACE) inhibitors, calcium-channel blockers (CCBs), ß-blockers, angiotensin-II receptor blockers (ARBs), or diuretics and followed-up for 24-months. Persistence on treatment was higher in patients treated with ARBs (68.5%) and ACE inhibitors (64.5%) vs CCBs (51.6%; p < 0.05), β-blockers (44.8%, p < 0.05), and diuretics (34.4%, p < 0.01). No ARB, ACE inhibitor, β-blocker, or diuretic was associated with a higher persistence in therapy compared with the other molecules used in each therapeutic class. The rate of persistence was significantly higher in patients treated with lercanidipine vs others CCBs (59.3% vs 46.6%, p < 0.05). Systolic and diastolic BP was decreased more successfully in patients treated with ARBs (–11.2/–5.8 mmHg), ACE inhibitors (–10.5/–5.1 mmHg), and CCBs (–8.5/–4.6 mmHg) compared with ß-blockers (–4.0/–2.3 mmHg p < 0.05) and diuretics (–2.3/–2.1 mmHg, p < 0.05). No ARB, ACE inhibitor, β-blocker, or diuretic was associated with a higher BP control compared with the other molecules used in each therapeutic class. A trend toward a better BP control was observed in response to lercanidipine vs other CCBs (p = 0.059). The present results confirm the importance of persistence on treatment for the management of hypertension in clinical practice.
Keywords: hypertension, antihypertensive drugs, persistence, blood pressure
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




